D.E. Shaw & Co
IMPL

D.E. Shaw & Co’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

D.E. Shaw & Co’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-27,142
Closed -$240K – 5338
2021
Q2 		$240K Buy
+27,142
New +$324K ﹤0.01% 4386

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
NVPX
Norwest Venture Partners XIV Palo Alto, California $60.4M AUM 9.56% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

D.E. Shaw & Co's IMPL Position: Q3 2021 in Review

D.E. Shaw & Co sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q3 2021, closing a stake of 27,142 shares — an estimated $240K sold.

D.E. Shaw & Co first reported a position in IMPL in Q2 2021 and held it in 1 quarter. The position peaked at $240K in Q2 2021. 44 funds tracked by Wall St. Rank hold IMPL as of Q3 2021.

  • D.E. Shaw & Co reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • D.E. Shaw & Co sold 27,142 Impel Pharmaceuticals Inc. Common Stock shares in Q3 2021, an estimated $240K.
  • D.E. Shaw & Co first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • D.E. Shaw & Co's Impel Pharmaceuticals Inc. Common Stock position peaked at $240K in Q2 2021.
  • 44 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q3 2021.

Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.